| Dr Shahram Tabib, MD | |
|
1420 S Central Ave, Glendale, CA 91204-2508 | |
| (818) 502-1900 | |
| Not Available |
| Full Name | Dr Shahram Tabib |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 26 Years |
| Location | 1420 S Central Ave, Glendale, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609819887 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | A69677 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Desert Valley Hospital | Victorville, CA | Hospital |
| Shasta Regional Medical Center | Redding, CA | Hospital |
| Southern Inyo Hospital | Lone pine, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Shasta Emergency Medical Associates Inc | 1052773983 | 17 |
| Southern Inyo Healthcare District | 7911816731 | 14 |
| Southland Emergency Medical Associates Inc | 9830466796 | 23 |
News Archive
Vismodegib, a new skin cancer drug for patients with advanced basal cell carcinoma tested by TGen, Virginia G. Piper Cancer Center at Scottsdale Healthcare and Mayo Clinic, is hailed as "the greatest advance in therapy yet seen" for advanced basal cell carcinoma in an editorial in the New England Journal of Medicine.
Exelixis, Inc. today reported updated interim data from the fully enrolled cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in a phase 2 adaptive randomized discontinuation trial (RDT).
After playing a central role in the negotiations, two health law tax provisions - one related to reinsurance and the other a levy on medical devices - appear to be off the table as of Wednesday morning. News outlets explained both in stories filed Tuesday night.
Resonant Medical, an innovator in 3D soft tissue planning, image-guidance and adaptive radiotherapy products, headquartered in Montreal, Canada, today announced that the Company is exhibiting the next generation of software for its Clarity System at the 51st annual American Society of Radiation Oncology (ASTRO) Annual Meeting taking place November 1-5, 2009 in Chicago.
In new research published in Endocrinology, Thomas Burris, Ph.D., chair of pharmacological and physiological science at Saint Louis University, reports that his team has found a way to prevent type I diabetes in an animal model.
› Verified 2 days ago
| Entity Name | Southern Inyo Healthcare District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831128602 PECOS PAC ID: 7911816731 Enrollment ID: O20040317000188 |
News Archive
Vismodegib, a new skin cancer drug for patients with advanced basal cell carcinoma tested by TGen, Virginia G. Piper Cancer Center at Scottsdale Healthcare and Mayo Clinic, is hailed as "the greatest advance in therapy yet seen" for advanced basal cell carcinoma in an editorial in the New England Journal of Medicine.
Exelixis, Inc. today reported updated interim data from the fully enrolled cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in a phase 2 adaptive randomized discontinuation trial (RDT).
After playing a central role in the negotiations, two health law tax provisions - one related to reinsurance and the other a levy on medical devices - appear to be off the table as of Wednesday morning. News outlets explained both in stories filed Tuesday night.
Resonant Medical, an innovator in 3D soft tissue planning, image-guidance and adaptive radiotherapy products, headquartered in Montreal, Canada, today announced that the Company is exhibiting the next generation of software for its Clarity System at the 51st annual American Society of Radiation Oncology (ASTRO) Annual Meeting taking place November 1-5, 2009 in Chicago.
In new research published in Endocrinology, Thomas Burris, Ph.D., chair of pharmacological and physiological science at Saint Louis University, reports that his team has found a way to prevent type I diabetes in an animal model.
› Verified 2 days ago
| Entity Name | Glendale Emergency Medical Associates, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588606834 PECOS PAC ID: 0648269001 Enrollment ID: O20040510001673 |
News Archive
Vismodegib, a new skin cancer drug for patients with advanced basal cell carcinoma tested by TGen, Virginia G. Piper Cancer Center at Scottsdale Healthcare and Mayo Clinic, is hailed as "the greatest advance in therapy yet seen" for advanced basal cell carcinoma in an editorial in the New England Journal of Medicine.
Exelixis, Inc. today reported updated interim data from the fully enrolled cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in a phase 2 adaptive randomized discontinuation trial (RDT).
After playing a central role in the negotiations, two health law tax provisions - one related to reinsurance and the other a levy on medical devices - appear to be off the table as of Wednesday morning. News outlets explained both in stories filed Tuesday night.
Resonant Medical, an innovator in 3D soft tissue planning, image-guidance and adaptive radiotherapy products, headquartered in Montreal, Canada, today announced that the Company is exhibiting the next generation of software for its Clarity System at the 51st annual American Society of Radiation Oncology (ASTRO) Annual Meeting taking place November 1-5, 2009 in Chicago.
In new research published in Endocrinology, Thomas Burris, Ph.D., chair of pharmacological and physiological science at Saint Louis University, reports that his team has found a way to prevent type I diabetes in an animal model.
› Verified 2 days ago
| Entity Name | Michael S. Agron, M.d., Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699716100 PECOS PAC ID: 2668360736 Enrollment ID: O20040707000788 |
News Archive
Vismodegib, a new skin cancer drug for patients with advanced basal cell carcinoma tested by TGen, Virginia G. Piper Cancer Center at Scottsdale Healthcare and Mayo Clinic, is hailed as "the greatest advance in therapy yet seen" for advanced basal cell carcinoma in an editorial in the New England Journal of Medicine.
Exelixis, Inc. today reported updated interim data from the fully enrolled cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in a phase 2 adaptive randomized discontinuation trial (RDT).
After playing a central role in the negotiations, two health law tax provisions - one related to reinsurance and the other a levy on medical devices - appear to be off the table as of Wednesday morning. News outlets explained both in stories filed Tuesday night.
Resonant Medical, an innovator in 3D soft tissue planning, image-guidance and adaptive radiotherapy products, headquartered in Montreal, Canada, today announced that the Company is exhibiting the next generation of software for its Clarity System at the 51st annual American Society of Radiation Oncology (ASTRO) Annual Meeting taking place November 1-5, 2009 in Chicago.
In new research published in Endocrinology, Thomas Burris, Ph.D., chair of pharmacological and physiological science at Saint Louis University, reports that his team has found a way to prevent type I diabetes in an animal model.
› Verified 2 days ago
| Entity Name | East Valley Emergency Medical Associates, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346287430 PECOS PAC ID: 3870579691 Enrollment ID: O20050506000210 |
News Archive
Vismodegib, a new skin cancer drug for patients with advanced basal cell carcinoma tested by TGen, Virginia G. Piper Cancer Center at Scottsdale Healthcare and Mayo Clinic, is hailed as "the greatest advance in therapy yet seen" for advanced basal cell carcinoma in an editorial in the New England Journal of Medicine.
Exelixis, Inc. today reported updated interim data from the fully enrolled cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in a phase 2 adaptive randomized discontinuation trial (RDT).
After playing a central role in the negotiations, two health law tax provisions - one related to reinsurance and the other a levy on medical devices - appear to be off the table as of Wednesday morning. News outlets explained both in stories filed Tuesday night.
Resonant Medical, an innovator in 3D soft tissue planning, image-guidance and adaptive radiotherapy products, headquartered in Montreal, Canada, today announced that the Company is exhibiting the next generation of software for its Clarity System at the 51st annual American Society of Radiation Oncology (ASTRO) Annual Meeting taking place November 1-5, 2009 in Chicago.
In new research published in Endocrinology, Thomas Burris, Ph.D., chair of pharmacological and physiological science at Saint Louis University, reports that his team has found a way to prevent type I diabetes in an animal model.
› Verified 2 days ago
| Entity Name | Golden West Emergency Medical Associates, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053680298 PECOS PAC ID: 8628098936 Enrollment ID: O20051201000582 |
News Archive
Vismodegib, a new skin cancer drug for patients with advanced basal cell carcinoma tested by TGen, Virginia G. Piper Cancer Center at Scottsdale Healthcare and Mayo Clinic, is hailed as "the greatest advance in therapy yet seen" for advanced basal cell carcinoma in an editorial in the New England Journal of Medicine.
Exelixis, Inc. today reported updated interim data from the fully enrolled cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in a phase 2 adaptive randomized discontinuation trial (RDT).
After playing a central role in the negotiations, two health law tax provisions - one related to reinsurance and the other a levy on medical devices - appear to be off the table as of Wednesday morning. News outlets explained both in stories filed Tuesday night.
Resonant Medical, an innovator in 3D soft tissue planning, image-guidance and adaptive radiotherapy products, headquartered in Montreal, Canada, today announced that the Company is exhibiting the next generation of software for its Clarity System at the 51st annual American Society of Radiation Oncology (ASTRO) Annual Meeting taking place November 1-5, 2009 in Chicago.
In new research published in Endocrinology, Thomas Burris, Ph.D., chair of pharmacological and physiological science at Saint Louis University, reports that his team has found a way to prevent type I diabetes in an animal model.
› Verified 2 days ago
| Entity Name | Pinnacle Emergency Physicians Of Bakersfield, A Professional Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619153251 PECOS PAC ID: 7214086321 Enrollment ID: O20090520000375 |
News Archive
Vismodegib, a new skin cancer drug for patients with advanced basal cell carcinoma tested by TGen, Virginia G. Piper Cancer Center at Scottsdale Healthcare and Mayo Clinic, is hailed as "the greatest advance in therapy yet seen" for advanced basal cell carcinoma in an editorial in the New England Journal of Medicine.
Exelixis, Inc. today reported updated interim data from the fully enrolled cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in a phase 2 adaptive randomized discontinuation trial (RDT).
After playing a central role in the negotiations, two health law tax provisions - one related to reinsurance and the other a levy on medical devices - appear to be off the table as of Wednesday morning. News outlets explained both in stories filed Tuesday night.
Resonant Medical, an innovator in 3D soft tissue planning, image-guidance and adaptive radiotherapy products, headquartered in Montreal, Canada, today announced that the Company is exhibiting the next generation of software for its Clarity System at the 51st annual American Society of Radiation Oncology (ASTRO) Annual Meeting taking place November 1-5, 2009 in Chicago.
In new research published in Endocrinology, Thomas Burris, Ph.D., chair of pharmacological and physiological science at Saint Louis University, reports that his team has found a way to prevent type I diabetes in an animal model.
› Verified 2 days ago
| Entity Name | Hollywood Presbyterian Emergency Medical Associates, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972826931 PECOS PAC ID: 7618006263 Enrollment ID: O20100520000454 |
News Archive
Vismodegib, a new skin cancer drug for patients with advanced basal cell carcinoma tested by TGen, Virginia G. Piper Cancer Center at Scottsdale Healthcare and Mayo Clinic, is hailed as "the greatest advance in therapy yet seen" for advanced basal cell carcinoma in an editorial in the New England Journal of Medicine.
Exelixis, Inc. today reported updated interim data from the fully enrolled cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in a phase 2 adaptive randomized discontinuation trial (RDT).
After playing a central role in the negotiations, two health law tax provisions - one related to reinsurance and the other a levy on medical devices - appear to be off the table as of Wednesday morning. News outlets explained both in stories filed Tuesday night.
Resonant Medical, an innovator in 3D soft tissue planning, image-guidance and adaptive radiotherapy products, headquartered in Montreal, Canada, today announced that the Company is exhibiting the next generation of software for its Clarity System at the 51st annual American Society of Radiation Oncology (ASTRO) Annual Meeting taking place November 1-5, 2009 in Chicago.
In new research published in Endocrinology, Thomas Burris, Ph.D., chair of pharmacological and physiological science at Saint Louis University, reports that his team has found a way to prevent type I diabetes in an animal model.
› Verified 2 days ago
| Entity Name | Can Emergency Physicians Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265810006 PECOS PAC ID: 8820304462 Enrollment ID: O20150827002595 |
News Archive
Vismodegib, a new skin cancer drug for patients with advanced basal cell carcinoma tested by TGen, Virginia G. Piper Cancer Center at Scottsdale Healthcare and Mayo Clinic, is hailed as "the greatest advance in therapy yet seen" for advanced basal cell carcinoma in an editorial in the New England Journal of Medicine.
Exelixis, Inc. today reported updated interim data from the fully enrolled cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in a phase 2 adaptive randomized discontinuation trial (RDT).
After playing a central role in the negotiations, two health law tax provisions - one related to reinsurance and the other a levy on medical devices - appear to be off the table as of Wednesday morning. News outlets explained both in stories filed Tuesday night.
Resonant Medical, an innovator in 3D soft tissue planning, image-guidance and adaptive radiotherapy products, headquartered in Montreal, Canada, today announced that the Company is exhibiting the next generation of software for its Clarity System at the 51st annual American Society of Radiation Oncology (ASTRO) Annual Meeting taking place November 1-5, 2009 in Chicago.
In new research published in Endocrinology, Thomas Burris, Ph.D., chair of pharmacological and physiological science at Saint Louis University, reports that his team has found a way to prevent type I diabetes in an animal model.
› Verified 2 days ago
| Entity Name | Team Physicians Of Southern California Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225499015 PECOS PAC ID: 0446545354 Enrollment ID: O20160816003061 |
News Archive
Vismodegib, a new skin cancer drug for patients with advanced basal cell carcinoma tested by TGen, Virginia G. Piper Cancer Center at Scottsdale Healthcare and Mayo Clinic, is hailed as "the greatest advance in therapy yet seen" for advanced basal cell carcinoma in an editorial in the New England Journal of Medicine.
Exelixis, Inc. today reported updated interim data from the fully enrolled cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in a phase 2 adaptive randomized discontinuation trial (RDT).
After playing a central role in the negotiations, two health law tax provisions - one related to reinsurance and the other a levy on medical devices - appear to be off the table as of Wednesday morning. News outlets explained both in stories filed Tuesday night.
Resonant Medical, an innovator in 3D soft tissue planning, image-guidance and adaptive radiotherapy products, headquartered in Montreal, Canada, today announced that the Company is exhibiting the next generation of software for its Clarity System at the 51st annual American Society of Radiation Oncology (ASTRO) Annual Meeting taking place November 1-5, 2009 in Chicago.
In new research published in Endocrinology, Thomas Burris, Ph.D., chair of pharmacological and physiological science at Saint Louis University, reports that his team has found a way to prevent type I diabetes in an animal model.
› Verified 2 days ago
| Entity Name | Grand Avenue Emergency Physicians Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962913632 PECOS PAC ID: 7315206653 Enrollment ID: O20180112002313 |
News Archive
Vismodegib, a new skin cancer drug for patients with advanced basal cell carcinoma tested by TGen, Virginia G. Piper Cancer Center at Scottsdale Healthcare and Mayo Clinic, is hailed as "the greatest advance in therapy yet seen" for advanced basal cell carcinoma in an editorial in the New England Journal of Medicine.
Exelixis, Inc. today reported updated interim data from the fully enrolled cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in a phase 2 adaptive randomized discontinuation trial (RDT).
After playing a central role in the negotiations, two health law tax provisions - one related to reinsurance and the other a levy on medical devices - appear to be off the table as of Wednesday morning. News outlets explained both in stories filed Tuesday night.
Resonant Medical, an innovator in 3D soft tissue planning, image-guidance and adaptive radiotherapy products, headquartered in Montreal, Canada, today announced that the Company is exhibiting the next generation of software for its Clarity System at the 51st annual American Society of Radiation Oncology (ASTRO) Annual Meeting taking place November 1-5, 2009 in Chicago.
In new research published in Endocrinology, Thomas Burris, Ph.D., chair of pharmacological and physiological science at Saint Louis University, reports that his team has found a way to prevent type I diabetes in an animal model.
› Verified 2 days ago
| Entity Name | Sound Physicians Emergency Medicine Of Southern California Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194180968 PECOS PAC ID: 9436406964 Enrollment ID: O20180716001079 |
News Archive
Vismodegib, a new skin cancer drug for patients with advanced basal cell carcinoma tested by TGen, Virginia G. Piper Cancer Center at Scottsdale Healthcare and Mayo Clinic, is hailed as "the greatest advance in therapy yet seen" for advanced basal cell carcinoma in an editorial in the New England Journal of Medicine.
Exelixis, Inc. today reported updated interim data from the fully enrolled cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in a phase 2 adaptive randomized discontinuation trial (RDT).
After playing a central role in the negotiations, two health law tax provisions - one related to reinsurance and the other a levy on medical devices - appear to be off the table as of Wednesday morning. News outlets explained both in stories filed Tuesday night.
Resonant Medical, an innovator in 3D soft tissue planning, image-guidance and adaptive radiotherapy products, headquartered in Montreal, Canada, today announced that the Company is exhibiting the next generation of software for its Clarity System at the 51st annual American Society of Radiation Oncology (ASTRO) Annual Meeting taking place November 1-5, 2009 in Chicago.
In new research published in Endocrinology, Thomas Burris, Ph.D., chair of pharmacological and physiological science at Saint Louis University, reports that his team has found a way to prevent type I diabetes in an animal model.
› Verified 2 days ago
| Entity Name | Southland Emergency Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932640935 PECOS PAC ID: 9830466796 Enrollment ID: O20220929003208 |
News Archive
Vismodegib, a new skin cancer drug for patients with advanced basal cell carcinoma tested by TGen, Virginia G. Piper Cancer Center at Scottsdale Healthcare and Mayo Clinic, is hailed as "the greatest advance in therapy yet seen" for advanced basal cell carcinoma in an editorial in the New England Journal of Medicine.
Exelixis, Inc. today reported updated interim data from the fully enrolled cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in a phase 2 adaptive randomized discontinuation trial (RDT).
After playing a central role in the negotiations, two health law tax provisions - one related to reinsurance and the other a levy on medical devices - appear to be off the table as of Wednesday morning. News outlets explained both in stories filed Tuesday night.
Resonant Medical, an innovator in 3D soft tissue planning, image-guidance and adaptive radiotherapy products, headquartered in Montreal, Canada, today announced that the Company is exhibiting the next generation of software for its Clarity System at the 51st annual American Society of Radiation Oncology (ASTRO) Annual Meeting taking place November 1-5, 2009 in Chicago.
In new research published in Endocrinology, Thomas Burris, Ph.D., chair of pharmacological and physiological science at Saint Louis University, reports that his team has found a way to prevent type I diabetes in an animal model.
› Verified 2 days ago
| Entity Name | Shasta Emergency Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356030563 PECOS PAC ID: 1052773983 Enrollment ID: O20230809003163 |
News Archive
Vismodegib, a new skin cancer drug for patients with advanced basal cell carcinoma tested by TGen, Virginia G. Piper Cancer Center at Scottsdale Healthcare and Mayo Clinic, is hailed as "the greatest advance in therapy yet seen" for advanced basal cell carcinoma in an editorial in the New England Journal of Medicine.
Exelixis, Inc. today reported updated interim data from the fully enrolled cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in a phase 2 adaptive randomized discontinuation trial (RDT).
After playing a central role in the negotiations, two health law tax provisions - one related to reinsurance and the other a levy on medical devices - appear to be off the table as of Wednesday morning. News outlets explained both in stories filed Tuesday night.
Resonant Medical, an innovator in 3D soft tissue planning, image-guidance and adaptive radiotherapy products, headquartered in Montreal, Canada, today announced that the Company is exhibiting the next generation of software for its Clarity System at the 51st annual American Society of Radiation Oncology (ASTRO) Annual Meeting taking place November 1-5, 2009 in Chicago.
In new research published in Endocrinology, Thomas Burris, Ph.D., chair of pharmacological and physiological science at Saint Louis University, reports that his team has found a way to prevent type I diabetes in an animal model.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Shahram Tabib, MD 8581 Santa Monica Blvd, 421, West Hollywood, CA 90069-4120 Ph: (310) 597-9786 | Dr Shahram Tabib, MD 1420 S Central Ave, Glendale, CA 91204-2508 Ph: (818) 502-1900 |
News Archive
Vismodegib, a new skin cancer drug for patients with advanced basal cell carcinoma tested by TGen, Virginia G. Piper Cancer Center at Scottsdale Healthcare and Mayo Clinic, is hailed as "the greatest advance in therapy yet seen" for advanced basal cell carcinoma in an editorial in the New England Journal of Medicine.
Exelixis, Inc. today reported updated interim data from the fully enrolled cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in a phase 2 adaptive randomized discontinuation trial (RDT).
After playing a central role in the negotiations, two health law tax provisions - one related to reinsurance and the other a levy on medical devices - appear to be off the table as of Wednesday morning. News outlets explained both in stories filed Tuesday night.
Resonant Medical, an innovator in 3D soft tissue planning, image-guidance and adaptive radiotherapy products, headquartered in Montreal, Canada, today announced that the Company is exhibiting the next generation of software for its Clarity System at the 51st annual American Society of Radiation Oncology (ASTRO) Annual Meeting taking place November 1-5, 2009 in Chicago.
In new research published in Endocrinology, Thomas Burris, Ph.D., chair of pharmacological and physiological science at Saint Louis University, reports that his team has found a way to prevent type I diabetes in an animal model.
› Verified 2 days ago
Cheryl Lee Jang, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1509 Wilson Ter, Emergency Department, Glendale, CA 91206 Phone: 818-863-4000 | |
Dr. Josiah Friedlander, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1420 S Central Ave, Glendale, CA 91204 Phone: 818-502-2344 Fax: 818-502-4501 | |
Dr. Gil Z Shlamovitz, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1812 Verdugo Blvd, Glendale, CA 91208 Phone: 818-790-7100 | |
Peter Utas, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1509 Wilson Ter, Emergency Department, Glendale, CA 91206 Phone: 818-409-8000 | |
Peter E Shin, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1509 Wilson Ter, Emergency Dept. - Glendale Adventist Medical Center, Glendale, CA 91206 Phone: 818-409-8000 | |
Dr. Ryan Raam, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1812 Verdugo Blvd, Glendale, CA 91208 Phone: 818-790-7100 | |
Dr. Jacob John Fakoory, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1420 S Central Ave, Glendale, CA 91204 Phone: 818-502-2344 Fax: 818-502-4501 |